Aravive (NASDAQ:ARAV) Price Target Raised to $12.00 at HC Wainwright

Aravive (NASDAQ:ARAV – Get Rating) had its price objective boosted by equities researchers at HC Wainwright from $7.00 to $12.00 in a research note issued to investors on Wednesday, The Fly reports. The firm presently has a “buy” rating on the stock.

Separately, EF Hutton Acquisition Co. I restated a “buy” rating and set a $10.00 price objective on shares of Aravive in a research note on Tuesday, February 14th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Aravive presently has a consensus rating of “Buy” and an average target price of $9.20.

Aravive Stock Up 13.7 %

Shares of NASDAQ ARAV opened at $1.83 on Wednesday. Aravive has a fifty-two week low of $0.58 and a fifty-two week high of $2.23. The firm’s 50-day simple moving average is $1.83 and its 200 day simple moving average is $1.40. The stock has a market cap of $109.49 million, a P/E ratio of -0.78 and a beta of 2.35.

Institutional Trading of Aravive

Several institutional investors and hedge funds have recently bought and sold shares of ARAV. Renaissance Technologies LLC grew its stake in Aravive by 35.0% during the 2nd quarter. Renaissance Technologies LLC now owns 374,945 shares of the company’s stock valued at $370,000 after acquiring an additional 97,116 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Aravive by 4.6% in the 4th quarter. Geode Capital Management LLC now owns 142,787 shares of the company’s stock valued at $188,000 after buying an additional 6,238 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Aravive in the 4th quarter valued at approximately $167,000. Millennium Management LLC grew its stake in shares of Aravive by 58.9% in the 2nd quarter. Millennium Management LLC now owns 96,838 shares of the company’s stock valued at $96,000 after buying an additional 35,900 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Aravive by 271.9% in the 4th quarter. Jane Street Group LLC now owns 42,115 shares of the company’s stock valued at $56,000 after buying an additional 30,792 shares in the last quarter. Institutional investors and hedge funds own 16.85% of the company’s stock.

About Aravive

(Get Rating)

Aravive, Inc operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression.